Background: The impact of amoxicillin resistance on the efficacy of regimens containing amoxicillin for Helicobacter pylori eradication remains unknown.
Introduction
Eradication of Helicobacter pylori may reduce the risk of recurrent peptic ulcer disease and may even reduce the risk of gastric cancer. 1, 2 However, the eradication rate of standard triple therapy is decreasing in many countries due to the increasing prevalence of antibiotic resistance. 3, 4 The efficacies of regimens containing clarithromycin and those containing levofloxacin have been shown to be greatly affected by clarithromycin and levofloxacin resistance, respectively. [5] [6] [7] [8] However, whether the eradication rate of regimens containing amoxicillin is affected by amoxicillin resistance remains unknown for the following reasons. First, few of the previous clinical trials provided information on amoxicillin resistance. 6, 7, 9, 10 Second, the numbers of patients with amoxicillin resistance were small because the primary amoxicillin resistance rate was ,3%-5% in the majority of countries. 6, 7, 10, 11 Therefore, the differences observed in those trials were usually not statistically significant. 7, 10 Third, the breakpoints for amoxicillin resistance varied between different trials. Although the EUCAST proposed breakpoint for amoxicillin resistance was .0.12 mg/L, 12 some researchers defined MICs 0.5 mg/L as resistant to amoxicillin in their trials. 9, 13 We have conducted five large randomized trials to compare the efficacy of different regimens in the first-and second-line treatment of H. pylori infection between 2007 and 2016 in Taiwan. [14] [15] [16] [17] [18] Culture and antibiotic susceptibility testing for H. pylori was done in subsets of patients. Therefore, we conducted this analysis of the five multicentre randomized trials to explore whether the efficacies of amoxicillin-containing regimens are affected by amoxicillin resistance. We also aimed to identify the breakpoint MICs for amoxicillin resistance that best correlate with the treatment efficacy of amoxicillin-containing triple therapy.
Patients and methods

Selection of study participants
Patients who received eradication therapies containing amoxicillin in any of the five multicentre, open-label, randomized trials from 2007 to 2016 in Taiwan were screened for eligibility. Patients aged 20 years with confirmed H. pylori infection were eligible for this study. Patients who met any of following criteria were excluded: allergy to proton pump inhibitors (PPIs) or study antibiotics, any use of study antibiotics within the previous 4 weeks, pregnant or lactating women, history of gastrectomy, severe concurrent diseases including malignancy, and those in whom the amoxicillin susceptibility testing for H. pylori was not available. Those who violated the study protocols were also excluded.
Regimens of each clinical trial
The regimens used in these trials included: clarithromycin triple therapy for 7 or 14 days; sequential therapy for 10 or 14 days; concomitant therapy for 10 days; levofloxacin triple therapy for 7 or 10 days; and levofloxacin sequential therapy for 10 days in the first-or second-line therapies were recruited in this study. The dosage and frequency of antibiotics used in each study are shown in Table 1 .
Ethics
All patients had signed the informed consents for these clinical trials. The protocol of this analysis had been approved by the Institutional Review Boards of the National University Hospital. 
Identification of H. pylori status
All participants received blood sampling for H. pylori antibody, 13 C-urea breath test ( 13 C-UBT), and upper endoscopy. Biopsy was done during endoscopic examination for rapid urease test, histological exam and microbiological culture. Any two positives of rapid urease test, histology, culture or serology were considered as H. pylori infection. Patients with a single positive 13 C-UBT were also eligible. The 13 C-UBT was performed for determination of H. pylori status at least 6 weeks after completing H. pylori treatment and a negative 13 C-UBT result was defined as successful eradication. Use of PPIs or histamine-2 blocker was not allowed for at least 2 weeks before 13 C-UBT. All breath samples were sent to Taiwan Institute of Pathology, Taipei, Taiwan where computer-generated results were produced by an infrared spectrometer. Positive results were defined as a delta value of 4 units and negative results as ,2.5 units. 19 
Culture for H. pylori and antibiotic susceptibility tests
The biopsy specimens from antrum were cultured on Brucella chocolate agar plates with 7% sheep blood. Under the microaerobic conditions with 5% O 2 , 10% CO 2 and 85% N 2 , these specimens were incubated for 7 days. The MICs were determined by the agar dilution method. In this study, we defined the resistance breakpoints of clarithromycin, levofloxacin and metronidazole as .1, .1 and 8 mg/L, respectively. T7, triple therapy for 7 days; T14, triple therapy for 14 days; S10, sequential therapy for 10 days; S14, sequential therapy for 14 days; LT7, levofloxacinbased triple therapy for 7 days; LT10, levofloxacin-based triple therapy for 10 days; LS10, levofloxacin-based sequential therapy for 10 days; C10, concomitant therapy for 10 days.
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Statistical analysis
Continuous data were expressed as the mean + SD and categorical data are expressed as percentages. The v 2 test with Yates' continuity correlation or Fisher's exact test was used to compare the eradication rate of two groups. We used the kappa coefficient to assess the agreement between amoxicillin resistance and eradication rate at different breakpoints of amoxicillin MICs. The strength of agreement by the kappa statistics was interpreted as follows: 0, poor; 0.10-0.20, slight; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80, substantial; and 0.81, almost perfect. 20, 21 In the present study, we used PP analysis to evaluate the impact of antibiotic resistance on treatment efficacy. Meta-analysis was performed to assess the risk ratio of eradication failure in amoxicillinresistant strains compared with susceptible strains of the seven different regimens using the random effects model. The primary outcome was expressed as risk ratio (RR) and 95% CI. The Q test was used to test the statistic heterogeneity between studies and P , 0.1 was considered significant. The I 2 statistic was used to quantify the heterogeneity (,25%, low; 25%-50%, moderate; and .50%, high). In the pooled analysis for patients treated with 7 or 14 day clarithromycin triple therapy, logistic regression model was used to calculate ORs and 95% CIs for the association between covariates and treatment. A two-tailed P , 0.05 was considered as significant. The meta-analyses were performed using the Comprehensive meta-analysis v2 software package (Biostat, Englewood, NJ, USA). The remaining analyses were performed using the SAS 9.4 software package (SAS Institute, Inc., Cary, NC, USA).
Results
Information of study participants
The flow diagram of this study is shown in Figure 1 . A total of 2501 patients who were treated with amoxicillin-containing regimens with available amoxicillin MIC data were assessed for eligibility. After excluding 162 patients who violated the study protocol of the clinical trials, a total of 2339 subjects were eligible for the present analysis. The demographic characteristics of the study subjects are shown in Table 2 . Among the 2339 eligible subjects, 1140 were men and 1199 were women. The mean age was 50.6+14.2 years and the mean BMI was 24.2+3.9 kg/m 2 . The prevalence of phenotypic resistance to amoxicillin (MIC 0.5 mg/L), clarithromycin (MIC .1 mg/L), levofloxacin (MIC .1 mg/L) and metronidazole (MIC 8 mg/L) were 2%, 14.5%, 12.5% and 26.9%, respectively. Patients were classified into five groups according to different regimens: triple therapy, sequential therapy, concomitant therapy, levofloxacin-based triple therapy and levofloxacin-based sequential therapy groups. In the triple therapy group receiving lansoprazole, clarithromycin and metronidazole, 133 subjects received conventional triple therapy for 7 days and the other 857 subjects received triple therapy for 14 days.
Meta-analysis of the impact of amoxicillin resistance on treatment failure
The primary outcome was the eradication rate of amoxicillinsusceptible group compared with the amoxicillin-resistant group by per protocol (PP) analysis. The treatment regimens used in each group were shown in Table 1 . Meta-analysis showed that amoxicillin resistance was consistently associated with an increased risk of treatment failure at different amoxicillin breakpoint MICs [ Figure 2 and Figure S1 (a-d), available as Supplementary data at JAC Online]. The RR was 1.41 (95% CI 1.12-1.78, P " 0.004) when the breakpoint MIC was 0.5 mg/L ( Figure S1a ). The heterogeneity was low (Q " 8.1, I
2 " 0%, P " 0.615, Figure S1a ). The RR was 1.27 (95% CI 1.13-1.44, P , 0.001) when the breakpoint MIC was 0.25 mg/L (Figure S1b T7, triple therapy for 7 days; T14, triple therapy for 14 days; S10, sequential therapy for 10 days; S14, sequential therapy for 14 days; LAC, lansoprazole, amoxicillin and clarithromycin; LAL, lansoprazole, amoxicillin and levofloxacin; LA-LCM, lansoprazole and ITT, intention to treat; PP, Per protocol C10, concomitant therapy for 10 days; LT7, Levofloxacin-based triple therapy for 7 days; LT10, Levofloxacin-based triple therapy for 10 days; LS10, Levofloxacin-based sequential therapy for 10 days amoxicillin, followed by lansoprazole, clarithromycin and metronidazole; LA-LLM, lansoprazole and amoxicillin, followed by lansoprazole, levofloxacin and metronidazole; LACM, lansoprazole, amoxicillin, clarithromycin and metronidazole 
Pooled analysis for patients treated with clarithromycin triple therapy
A total of 990 patients treated with 7 or 14 day triple therapy were included in the pooled analysis. We found that the presence of amoxicillin resistance was associated with a lower eradication rate at different breakpoints (Table 3 ). The highest kappa coefficient was observed when the amoxicillin breakpoint MIC was 0.125 mg/L. However, the kappa coefficient (0.298) was interpreted as only fair agreement (Table 3 ). In the univariate logistic regression analysis, the amoxicillin MIC of 0.5 mg/L was associated with increased risk of treatment failure (OR " 14.1; 95% CI 5.0-39.6). In the Chen et al.
multivariate regression analysis, only amoxicillin resistance (adjusted OR 34.3) and clarithromycin resistance (adjusted OR 14.5) were significantly associated with eradication failure (Table 4) . We further showed that amoxicillin resistance was associated with treatment failure at different MIC breakpoints (1, 0.5, 0.25, 0.125, 0.06 or 0.03 mg/L, Table 5 ). The prevalence of amoxicillin resistance was 1.6%, 4.3% and 11.1% when the breakpoint was 0.5, 0.25 and 0.125 mg/L, respectively (Table 5) . We then assessed the eradication rate of triple therapy according to the single and dual resistance to clarithromycin and amoxicillin at different breakpoints ( Table 6 ). The eradication rates were 95.3%, 75.3%, 58.2% and 16% in strains with dual susceptible, Amoxicillin resistance and eradication of H. pylori JAC single amoxicillin resistance, single clarithromycin resistance and dual resistance to both antibiotics, respectively, when the amoxicillin breakpoint was 0.125 mg/L ( Table 6 ). The findings were similar when the amoxicillin resistance breakpoints were 0.5, 0.25, 0.125 and 0.06 mg/L (Table 6 ).
Discussion
To our knowledge, this combined analysis including five clinical trials is the first to show that the presence of amoxicillin resistance was consistently associated with treatment failure in patients treated with amoxicillin-containing regimens (RR 1.41; 95% CI 1.12-1.78 when the breakpoint was 0.5 mg/L). The heterogeneity of the included trials was low. We further showed that amoxicillin resistance was an independent risk factor of treatment failure of 7 or 14 day clarithromycin triple therapy at different MIC breakpoints in both the univariate and multivariate logistic regression models. The best correlation between amoxicillin resistance and treatment failure was observed when the breakpoint of amoxicillin resistance was 0.125 mg/L, at which the prevalence of amoxicillin resistance would be 11.1% (110 of 990). The strength of this study included the large sample size and the use of collected strains and clinical information within prospectively conducted randomized trials. We used similar inclusion criteria, diagnostic criteria for H. pylori infection, and the same agar dilution test for MIC determinations in these Chen et al.
trials. The raw amoxicillin MIC data were available, which allowed us to identify the effect of amoxicillin resistance on the efficacy of amoxicillin-containing regimens at different MIC breakpoints.
Owing to its low prevalence, the impact of amoxicillin resistance on the treatment failure of regimens containing amoxicillin has long been ignored. 22 A worldwide review published in 2004 showed the prevalence of amoxicillin resistance was nil or ,1%.
23
The summary prevalence of amoxicillin resistance was 4% in a systematic review in Latin Americans. 24 The primary resistance rate of amoxicillin in our study was quite low (2.0% at the MIC breakpoint of 0.5 mg/L), which was similar to most countries. 25 However, there were higher resistance rates to amoxicillin in some countries; e.g. resistance rates were 8.8% in Korea and 65.6% in Africa, respectively. 26 The differences in the methods used to determine the MICs and the differences in the MIC breakpoints might contribute to the difference in the prevalence of amoxicillin resistance. The results from our study showed that the prevalence of amoxicillin resistance would increase from 1.6% to 4.3% and 11.1% when the breakpoint of resistance was reduced from 0.5 to 0.25 and 0.125 mg/L, respectively. Besides, resistance to amoxicillin in H. pylori may be gradually induced and higher resistance rates of amoxicillin were observed after unsuccessful eradication. 27 The prevalence of amoxicillin resistance is also higher in patients failing after one or more eradication therapies. These collectively underscore the importance of amoxicillin resistance in the treatment of H. pylori infection.
To validate the findings from this analysis, we further conducted a systematic review of the literature to identify clinical trials that reported the impact of amoxicillin resistance on the efficacy of PPI/clarithromycin/amoxicillin triple therapy. The detailed methods and results are described in the Supplementary data. In brief, the PubMed database was searched using the keywords 'H. pylori and eradication and triple therapy and resistance and amoxicillin'. Those studies that were duplicate, irrelevant to our topic, regimens not containing amoxicillin, lack of data on amoxicillin susceptibility, lack or incomplete data of eradication rate according to amoxicillin resistance, or lack of amoxicillin-resistant strains were excluded. Amoxicillin resistance was determined in 78 trials. We found that the defined breakpoints of amoxicillin resistance among these different studies varied greatly from .0.12 to .8 mg/L (Table S1 ). The prevalence of amoxicillin resistance was 0% in 50 trials and the eradication rate according to amoxicillin resistance was not reported in 17 trials (Table S1 and Figure S2 ). Of the 11 eligible trials, four were conducted by our group and another seven were conducted by other groups ( Figure S2 and Table S2 ). Meta-analysis of the seven trials showed that amoxicillin resistance appeared to be associated with increased risk of treatment failure, but the difference was not statistically significant (RR 1.15, 95% CI 1.00-1.34, P " 0.057, Figure S3a ). The impact of amoxicillin resistance on efficacy in these seven trials was analysed according to the ITT analysis, which also included patients with poor compliance or lost to follow-up. This might lead to bias toward the null hypothesis and could partly explain the non-statistically significant difference in the meta-analysis of the seven trials. When the four trials conducted by our group were included in the meta-analysis, we found that amoxicillin resistance was significantly associated with increased risk of treatment failure of PPI/clarithromycin/ amoxicillin triple therapy (RR 1.27, 95% CI 1.12-1.44, P , 0.001, Figure S3b ).
The optimal breakpoint of amoxicillin resistance for H. pylori infection remains controversial. Although the EUCAST defined the MIC of .0.125 mg/L as amoxicillin resistance for H. pylori, [28] [29] [30] [31] amoxicillin resistance was not defined by the CLSI. In the present study, we showed that the association of treatment failure and amoxicillin resistance was consistently observed at different MIC breakpoints. We observed better correlation when the breakpoint of amoxicillin resistance was 0.125 mg/L, although the degree of agreement was only fair (kappa coefficient 0.298). The results could provide evidence for deciding the breakpoint of amoxicillin resistance for H. pylori and susceptibility testing for amoxicillin might be needed to choose the regimens for H. pylori eradication in future clinical practice. As 23S rRNA and gyrase A mutations have been shown to be associated with clarithromycin and levofloxacin resistance, respectively, 32 further studies are needed to assess whether the mutations in penicillin-binding proteins 1, 2 and 3 are associated with amoxicillin resistance and treatment failure. 33 Amoxicillin resistance and eradication of H. pylori JAC Nevertheless, there are some limitations of the present study. First, this study enrolled patients from 2007 to 2016 and the prevalence of antibiotic resistance may change with time. However, our previous study showed the primary resistance of amoxicillin remained stable in Taiwan during this period. 34 Therefore, such bias could be minimized. The second limitation is the heterogeneity in the amoxicillin-containing regimens used in the five trials. Therefore, meta-analysis was used to assess the effect of amoxicillin resistance on treatment failure among the five trials. To determine the optimal breakpoints of amoxicillin MIC, we only included treatment-naive patients who received first-line clarithromycin triple therapy. Third, we analysed the effect of amoxicillin resistance on treatment failure in patients who complied with the study protocol. This might lead to selection bias. However, our previous trials have shown that the characteristics among patients who violated and complied with the study protocol were similar. Finally, this was a pooled analysis of five randomized trials. However, the association with amoxicillin resistance and treatment failure is biologically plausible and is not attributed to the multiple comparison of the exploratory analysis.
In conclusion, we demonstrated that the presence of amoxicillin resistance was associated with treatment failure of H. pylori in regimens containing amoxicillin. The effect was observed at different amoxicillin MIC breakpoints for PPI/clarithromycin/amoxicillin triple therapy. The best correlations between amoxicillin resistance and treatment failure were observed when the breakpoint of amoxicillin resistance was 0.125 mg/L, at which the prevalence of amoxicillin resistance would be substantial (11.1%, 110 of 990). The results from this study provide evidence to support the .0.12 mg/L breakpoint for amoxicillin resistance proposed by EUCAST. Clinicians should pay more attention to amoxicillin resistance in the treatment of H. pylori infection in their future clinical practice.
